{"filings":[{"id":90492,"accession_number":"0001628280-26-030924","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax Q1 revenue $140M, net loss $9M; Pfizer Matrix-M deal adds $30M upfront","event_type":"earnings","confidence":"high","bullets":["Total revenue $140M, down 79% YoY; prior-year included $603M non-cash APA close-out.","Net loss $9M vs net income $519M in Q1 2025; cash $795M, up from $751M.","Pfizer non-exclusive Matrix-M license yielded $30M upfront, potential milestones up to $500M.","Matrix-M partnering expanded: four top-10 pharma companies exploring over 30 fields; new MTAs signed.","FY 2026 guidance reiterated: Non-GAAP combined R&D+SG&A $310-340M; cash position strengthened by $330M credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":139514000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100038,"accession_number":"0001000694-26-000011","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax Q4 net income $18M, full-year profit $440M; Pfizer Matrix-M license deal","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $147M (+67% YoY); net income $18M vs $81M loss in Q4 2024.","Full year 2025 revenue $1.12B (+65% YoY); net income $440M vs $187M loss in 2024.","Jan 2026: non-exclusive Pfizer license for Matrix-M in two areas; $30M upfront, up to $500M milestones plus royalties.","Cash $751M at Dec 2025 (down from $938M); Feb 2026 $330M credit facility from MidCap Financial, initial $50M draw.","Cost reductions exceed goals; 2026 Non-GAAP R&D+SG&A target $310-340M, falling to ≤$200M by 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":1123479000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100037,"accession_number":"0001104659-26-004785","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Novavax licenses Matrix-M adjuvant to Pfizer for up to $500M milestones plus royalties","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $30M in Q1 2026; eligible for up to $500M in milestones ($70M development, $180M sales per field).","Tiered high mid-single digit royalties on net sales until later of 20 years or patent expiry.","Non-exclusive worldwide license for up to two infectious disease fields; first field selected, second at Pfizer's option.","Pfizer controls development, manufacturing, and commercialization; separate supply agreements to be finalized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100036,"accession_number":"0001104659-26-002725","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Novavax presents strategic update at J.P. Morgan; 2025 results pending","event_type":"other_material","confidence":"low","bullets":["Preliminary financial results for year ended Dec 31, 2025 are being finalized and subject to change.","No specific financial metrics disclosed; presentation focuses on strategic and business updates.","Investor presentation delivered at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.","Company cautions that actual results may differ materially from preliminary data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116385,"accession_number":"0001000694-25-000048","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax Q3 net loss $202M, revenue down to $70M; raises FY2025 revenue guidance","event_type":"earnings","confidence":"high","bullets":["Total revenue $70M, down 18% YoY from $85M; product sales (Nuvaxovid) $0 vs $38M.","Net loss $202M vs $121M YoY; includes $97M asset impairment from Maryland site consolidation.","Cash $778M as of Sep 30, 2025; completed convertible debt refinancing extending maturities to 2031.","Sanofi milestones $225M YTD; $50M earned on marketing authorization transfers in Q4 2025.","Maryland site consolidation yields $60M cash proceeds, ~$230M cost savings over 11 years."],"consensus_eps_estimate":null,"consensus_eps_actual":2.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":976340000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116384,"accession_number":"0001104659-25-105818","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Novavax completes U.S. marketing authorization transfer to Sanofi for Nuvaxovid, earns $25M milestone","event_type":"other_material","confidence":"high","bullets":["FDA approved transfer of U.S. marketing authorization for Nuvaxovid from Novavax to Sanofi on Nov 3, 2025.","Second $25M milestone payment triggered; follows EU transfer in Oct 2025. Payment expected Q1 2026.","Total non-dilutive capital secured YTD 2025 from Sanofi milestones is $225M.","Sanofi now responsible for U.S. commercial and regulatory activities for Nuvaxovid.","CEO John C. Jacobs notes delivery on partnership obligations and future royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116383,"accession_number":"0001104659-25-101390","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["1.01","2.06","8.01","9.01"],"status":"ready","headline":"Novavax enters lease assignment and asset sales with AstraZeneca for $59.8M; expects Q3 non-cash charges of $125-127M","event_type":"other_material","confidence":"high","bullets":["Assignment fee $15M, parcel sale $20M, asset sale $24.8M; total $59.8M from AstraZeneca.","Non-cash impairment of $96-98M in Q3 2025 from these transactions, plus $29M from convertible note extinguishment.","Parcel sale closes Q4 2025; lease assignment and asset sale close Q1 2026.","Novavax pays base rent for Jan-Jun 2026 under lease assignment; AstraZeneca responsible thereafter.","Corporate headquarters relocated from 700 Quince Orchard Rd to 21 Firstfield Rd, Gaithersburg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116382,"accession_number":"0001104659-25-097317","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Novavax completes Nuvaxovid EU marketing authorization transfer to Sanofi; triggers $25M milestone","event_type":"other_material","confidence":"high","bullets":["European Commission approved transfer of Nuvaxovid EU marketing authorization from Novavax CZ to Sanofi Winthrop Industrie.","Milestone payment of $25M triggered; Novavax expects receipt in Q1 2026.","Additional milestones: $25M for U.S. transfer, $75M for technology transfer, up to $350M for combo products.","Novavax eligible for tiered royalties on Sanofi's standalone COVID vaccine and combination products.","CEO John Jacobs: successful transfer is another step in ensuring global access to protein-based COVID vaccine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132828,"accession_number":"0001104659-25-084053","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Novavax issues $225M 4.625% convertible notes due 2031, exchanges $148.7M of 2027 notes","event_type":"debt","confidence":"high","bullets":["Issued $225M principal of 4.625% Convertible Senior Notes due 2031; initial conversion price ~$11.14 (27.5% premium).","Exchanged ~$175.3M of new notes for ~$148.7M of existing 5.00% 2027 notes; $49.7M for cash.","Notes mature Sept 1, 2031; interest payable semi-annually; redeemable by company after Sept 5, 2028 if stock >130% of conversion price.","Maximum dilution: 25,743,690 shares upon conversion at max conversion rate $8.74 per share.","Exchange portion unregistered under Section 3(a)(9); shares upon conversion also exempt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132827,"accession_number":"0001104659-25-084049","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves Novavax's Nuvaxovid 2025-2026 COVID-19 vaccine for high-risk populations","event_type":"regulatory","confidence":"high","bullets":["Approved for adults 65+ and high-risk individuals 12-64; only protein-based non-mRNA COVID-19 vaccine available in U.S. for 2025-2026 season.","Shelf life extended from 3 to 6 months for the 2025-2026 formula.","FDA requires two postmarketing studies: a Phase 3 safety/immunogenicity study and a Phase 4 placebo-controlled trial on post-COVID vaccination syndrome.","Sanofi to lead commercialization; Novavax receives tiered royalties on sales.","Clinical data show JN.1 strain induces immunity against multiple JN.1 lineage variants including NB.1.8.1 and XEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132826,"accession_number":"0001104659-25-081160","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Novavax issues $225M in 4.625% convertible notes due 2031, refinancing 2027 notes","event_type":"debt","confidence":"high","bullets":["Issued $225M of 4.625% Convertible Senior Notes due 2031; exchanged ~$148.7M of 2027 notes and raised ~$49.7M new cash.","Conversion price $11.14 per share, a 27.5% premium over the Aug 20 closing price of $8.74.","Approximately $26.5M of 2027 notes remain outstanding; net proceeds from subscription for general corporate purposes.","Closing expected on or about Aug 27, 2025; financial advisor JWCA plans to buy ~1.2M shares concurrently."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132825,"accession_number":"0001000694-25-000031","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novavax Q2 revenue $239M; net income $107M; $175M Sanofi milestone from FDA BLA approval","event_type":"earnings","confidence":"high","bullets":["Total revenue of $239M, down 42% YoY, includes $175M milestone from Nuvaxovid BLA approval.","Net income of $107M vs $162M YoY; cash $628M; $175M milestone receipt expected Q3 2025.","Updated FY2025 adjusted total revenue guidance to $1,000-1,050M (prior $975-1,025M).","Combined R&D/SG&A expense guidance raised to $495-545M; includes $20M postmarketing study cost.","Phase 3 data for COVID-flu combo and standalone flu candidates showed robust immune responses."],"consensus_eps_estimate":null,"consensus_eps_actual":3.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":905895000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149382,"accession_number":"0001104659-25-061874","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Novavax stockholders elect directors, approve advisory compensation, ratify auditor at 2025 annual meeting","event_type":"other","confidence":"high","bullets":["Elected Class III directors Rachel K. King, John W. Shiver, and Charles W. Newton (each with majority 'For' votes).","Advisory vote on named executive officer compensation approved: 41,390,651 For, 15,830,308 Against.","Ratification of Ernst & Young as auditor for FY2025 approved: 79,306,893 For, 15,057,873 Against.","Quorum of 95,359,194 shares present; total outstanding shares were 161,968,503 as of record date April 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149381,"accession_number":"0001104659-25-058379","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novavax Phase 3 CIC & flu vaccine candidates show robust immune responses, well tolerated","event_type":"other_material","confidence":"high","bullets":["COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine candidates induced 2.4-5.7-fold immune responses over baseline.","Both candidates well tolerated; >98% of solicited adverse events mild or moderate in severity.","Results from initial cohort of Phase 3 trial in adults 65+; similar to licensed comparators Nuvaxovid and Fluzone HD.","Novavax continues to pursue partnering opportunities to advance further development of these programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149380,"accession_number":"0001104659-25-052959","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Novavax eliminates COO role; John Trizzino to depart June 20, 2025","event_type":"leadership","confidence":"high","bullets":["COO position eliminated; John Trizzino's employment terminated effective June 20, 2025.","Separation pay of $601,778 lump sum plus up to 12 months COBRA premiums.","Consulting agreement June 20 to Dec 31, 2025 at $15,000/month; equity continues vesting during period.","Unvested options from March 2023 grant will fully vest upon consulting agreement termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149379,"accession_number":"0001104659-25-050226","cik":1000694,"company_name":"NOVAVAX INC","ticker":"NVAX","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Novavax receives FDA approval for Nuvaxovid COVID-19 vaccine; triggers $175M Sanofi milestone","event_type":"regulatory","confidence":"high","bullets":["FDA approves BLA for Nuvaxovid for COVID-19 in adults 65+ and high-risk individuals 12-64.","Approval triggers $175M milestone payment from Sanofi under May 2024 Collaboration and License Agreement.","FDA requests new Phase 4 postmarketing efficacy trial in 50-64 age group without high-risk conditions; Novavax working with Sanofi on funding.","Novavax reiterates FY2025 R&D+SG&A guidance of $475-525M; projects ~$350M for FY2026 and ~$250M for FY2027.","Expects commercial delivery of 2025-2026 COVID-19 vaccine formula in US this Fall with Sanofi, pending VRBPAC recommendation May 22."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}